EpiTherapeutics approaches the clinic
The deficit swelled in 2014 for the Danish-based biotech company EpiTherapeutics, which is now exploring options for additional funding, just as it is edging closer to clinical trials.
BY BENJAMIN WERNER CHRISTENSEN
2014 was a year that lived up to the expectations for the Danish-based biotech company EpiTherapeutics and not much more than that, although the company has edged closer to clinical phases and is now exploring options for raising additional funds.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
EpiTherapeutics brings in Merck’s oncology deputy
For abonnenter
Randi Krogsgaard leaves Dansk Biotek
For abonnenter
”There’s more money than there has been in years”
For abonnenter
